Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-L1
Biotech
Moderna plants new cancer vaccine trials, weeds PD-L1 work
Moderna ended development of a preclinical PD-L1-targeting therapy while deepening work on a Merck-partnered neoantigen med.
Max Bayer
May 2, 2024 11:00am
Combo may offer route back for Agenus' cervical cancer drug
Jan 23, 2023 10:47am
Could beta cells be the source of Type 1 diabetes after all?
Jul 5, 2022 8:25am
Checkpoint on track to add indications for cancer drug approval
Jun 16, 2022 3:49pm
Agenus, with FDA approval in sight, showcases anti-PD-1 data
Aug 27, 2021 7:55am
Arcus, Gilead post scant analysis of clinical data on TIGIT drug
Jun 24, 2021 7:30am